Cumulus

Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project  

Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has...

Cumulus Neuroscience Commences Clinical Studies of Digital Biomarker Platform in Degenerative Neurological Diseases

Belfast, UK - 25 May 2022. Cumulus Neuroscience, a global digital health company, announces the start of two validation trials - CNS-101 and CNS-102 - supported by a group of leading global pharma companies and Innovate UK. The studies will investigate the potential benefits of Cumulusí integrated physiological and digital biomarker platform in quantifying cognitive...
Belfast The Innovation Centre Queens Rd, Belfast, BT3 9DT

+44 (0)28 9264 6600